Objective: To estimate the prevalence, annual mortality, and geographic distribution of Wegener's granulomatosis.
Methods: Analysis of national vital statistics data and hospitalization data from a national survey and from all New York State inpatient facilities.
Results: Between 1979 and 1988, 1,784 death certificates in the United States listed Wegener's granulomatosis as a cause of death. Nationally, an estimated 10,771 hospitalizations included Wegener's granulomatosis among the discharge diagnoses. In New York State, there were 978 hospitalizations among 571 individuals with Wegener's granulomatosis.
Conclusion: The prevalence of Wegener's granulomatosis in the United States is approximately 3.0 per 100,000 persons. Clear differences in the geographic distribution of Wegener's granulomatosis are apparent when analysis consider rates of disease in individual counties. Contrary to previous reports, associations between disease exacerbations and season were not apparent.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/art.1780390112 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Purpose: This study investigates the capabilities of ultrasonography (US) in determing the stage of orbital inflammation in patients with granulomatosis with polyangiitis (GPA).
Material And Methods: The study included 24 patients (8 men and 16 women) with diffuse orbital tissue involvement in GPA. Group 1 (active stage) included nine patients, while group 2 (inactive stage) consisted of 18 patients.
[Granulomatosis with polyangiitis. Analysis of two clinical cases from the practice of an otorhinolaryngologist].
Vestn Otorinolaringol
December 2024
Pavlov Ryazan State Medical University, Ryazan, Russia.
The article presents an analysis of 2 clinical cases of granulomatosis with polyangiitis from the practice of an otorhinolaryngologist. In the first case, the pathology manifested with lesions of the middle ear and nose. In the second case, in addition to manifestations from the nose and the ear, there was a lesion of the larynx.
View Article and Find Full Text PDFA Unique Case Linking Rituximab to a Ureaplasma Infection and Life-Threatening Hyperammonemia.
Cureus
November 2024
Pulmonary & Critical Care, Indiana University Health Methodist Hospital, Indianapolis, USA.
Rituximab is an anti-CD20 monoclonal antibody medication used in treating various cancers like non-Hodgkin lymphomas as well as immunologic conditions like granulomatosis with polyangiitis. It disrupts and decreases the number of B-cells, which causes an immunosuppressive state. This can promote the growth of numerous rare and opportunistic pathogens, one of which is .
View Article and Find Full Text PDFRemission induction therapies and long-term outcomes in granulomatosis with polyangiitis and microscopic polyangiitis: real-world data from a European cohort.
Rheumatol Int
December 2024
Department of Nephrology and Clinical Immunology, RWTH Aachen University Hospital, Pauwelsstraße 30, 52074, Aachen, Germany.
To explore disease characteristics, renal involvement and induction treatment strategies over the last decades and evaluate relapse rates and renal outcomes in ANCA-associated vasculitides (AAV). We retrospectively analyzed remission, relapse rates and the occurrence of the composite endpoint (comprising death and renal failure) in newly diagnosed AAV cases in four tertial referral centers in Germany and Switzerland diagnosed between 1999 and 2022. Hazard ratios were computed by Cox proportional hazard and Kaplan-Meier curves were plotted to compare therapeutic strategies after propensity-matching.
View Article and Find Full Text PDFGlucocorticoid tapering pace in microscopic polyangiitis and granulomatosis with polyangiitis in Japanese real-world practice: A propensity score-matched retrospective cohort study from the J-CANVAS registry.
Mod Rheumatol
December 2024
Department of Nephrology and Rheumatology, Graduate School of Medical Science, Kanazawa University.
Objective: To assess the prevalence and outcomes among regimens of glucocorticoid tapering for microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) in real-world practice.
Methods: We retrospectively examined the Japan Collaborative Registry of ANCA-associated Vasculitis (J-CANVAS) registry, and evaluated the prevalence of glucocorticoid tapering regimens in the PEXIVAS trial. In patients with newly diagnosed MPA and GPA, we compared outcomes among standard and reduced pace regimens.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!